Statement of Ownership (sc 13g)
November 04 2021 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ___)
PASITHEA THERAPEUTICS CORP.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
70261F103
(CUSIP Number)
November 4, 2021
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
Check the appropriate box to designate the rule pursuant to which
this Schedule is filed: ☒ Rule 13d-1(c)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise
subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following page(s)
Page 1 of 5 Pages
CUSIP
No. 70261F103
|
|
13G
|
Page
2 of 5 Pages
|
1.
|
NAMES OF REPORTING PERSON
|
|
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
|
|
|
|
Alpha Capital Anstalt
|
2.
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
|
|
(a) ☐
|
|
(b) ☐
|
3.
|
SEC USE ONLY
|
|
|
4.
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
|
Liechtenstein
|
5.
|
SOLE VOTING POWER, NUMBER OF SHARES BENEFICIALLY
OWNED BY EACH REPORTING PERSON – 831,755 Shares of Common Stock (1)
|
|
|
6.
|
SHARED VOTING POWER – None
|
|
|
7.
|
SOLE DISPOSITIVE POWER – 831,755 Shares of Common Stock (1)
|
|
|
8.
|
SHARED DISPOSITIVE POWER – None
|
|
|
9.
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON -
|
|
|
|
|
|
831,755 Shares of Common Stock (1)
|
|
10.
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
|
|
|
|
☒
|
|
The aggregate amount in Row 9 represents the maximum amount that Alpha
Capital Anstalt can beneficially control under a contractually stipulated 4.99% ownership restriction. The full conversion and/or exercise
of Alpha Capital Anstalt’s securities would exceed this restriction.
|
|
11.
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
|
|
|
|
|
|
6.36% (1)
|
|
12.
|
TYPE OF REPORTING PERSON
|
|
|
|
|
|
CO
|
|
(1) Based on 13,058,371 shares outstanding as of November 4, 2021.
CUSIP
No. 70261F103
|
|
13G
|
Page
3 of 5 Pages
|
ITEM 1 (a) NAME OF ISSUER: Pasithea Therapeutics Corp., a Delaware corporation
ITEM 1 (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
1111 Lincoln Road, Suite 500, Miami Beach, FL 33139
ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt
ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein
ITEM 2 (c) CITIZENSHIP: Liechtenstein
ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock
ITEM 2 (e) CUSIP NUMBER: 70261F103
ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B):
Not applicable
ITEM 4 OWNERSHIP
(a) AMOUNT BENEFICIALLY OWNED: 831,755 Shares of Common Stock (1)
(b) PERCENT OF CLASS: 6.36% (1)
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR DIRECT THE VOTE
831,755 Shares of Common Stock (1)
(ii) SHARED POWER TO VOTE OR DIRECT THE VOTE
0 Shares
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION
OF
831,755 Shares of Common Stock (1)
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE
DISPOSITION OF
0 Shares
CUSIP
No. 70261F103
|
|
13G
|
Page
4 of 5 Pages
|
ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
Not applicable
ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Not applicable
ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable
ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP
Not applicable
ITEM 9 NOTICE OF DISSOLUTION OF GROUP
Not applicable
CUSIP
No. 70261F103
|
|
13G
|
Page
5 of 5 Pages
|
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
November 4, 2021
|
|
(Date)
|
|
|
|
/s/ Konrad Ackermann
|
|
(Signature)
|
|
|
|
Konrad Ackermann, Director
|
|
(Name/Title)
|
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Sep 2023 to Sep 2024